Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study.

ABSTRACT: Introduction: Immune checkpoint inhibitors (ICIs) exert antitumor responses in many types of cancer but may also induce serious or fatal toxicities that affect all organ systems, including the hematologic and lymphatic systems. However, the risk of hematologic and lymphatic system toxicities following different ICI treatments remains unknown. This study aimed to describe the hematologic and lymphatic system toxicities associated with different ICI regimens and the impact of combining ICIs with anti-vascular endothelial growth factor drugs using the United States Food and Drug Administration Adverse Event Reporting System pharmacovigilance database. Methods: The reporting odds ratio (ROR) and information component (IC) indices were used to identify disproportionate reporting o

SUBMITTER: Li N 

PROVIDER: S-EPMC10644043 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature